{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:11:39Z","timestamp":1782688299566,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,20]]},"DOI":"10.7759\/cureus.92794","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T17:09:31Z","timestamp":1758388171000},"source":"Crossref","is-referenced-by-count":1,"title":["Pioglitazone as Add-On to Metformin and Dapagliflozin Yields Significant Enhancements in Glycemic Control in Poorly Controlled Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Sara","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alquddosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah M","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Mesbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hamouda","family":"Elkasaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149239","article-title":"The crucial role and mechanism of insulin resistance in metabolic disease","volume":"14","author":"Zhao X","year":"2023","unstructured":"Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol (Lausanne). 2023, 14:1149239. 10.3389\/fendo.2023.1149239","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan MA","year":"2020","unstructured":"Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020, 10:107-11. 10.2991\/jegh.k.191028.001","journal-title":"J Epidemiol Glob Health"},{"key":"ref3","article-title":"Global picture","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. Global picture. IDF Diabetes Atlas. International Diabetes Federation , Brussels, Belgium; 2021."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26180","article-title":"Glycemic control for type 2 diabetes mellitus patients: a systematic review","volume":"14","author":"Bin Rakhis SA Sr","year":"2022","unstructured":"Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic control for type 2 diabetes mellitus patients: a systematic review. Cureus. 2022, 14:e26180. 10.7759\/cureus.26180","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020","volume":"43","year":"2020","unstructured":"2. Classification and diagnosis of diabetes. standards of medical care in diabetes-2020. Diabetes Care. 2020, 43:S14-31. 10.2337\/dc20-S002","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012906.pub2","article-title":"Metformin monotherapy for adults with type 2 diabetes mellitus","volume":"6","author":"Gnesin F","year":"2020","unstructured":"Gnesin F, Thuesen AC, K\u00e4hler LK, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020, 6:CD012906. 10.1002\/14651858.CD012906.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu B","year":"2022","unstructured":"Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022, 21:83. 10.1186\/s12933-022-01512-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15526","article-title":"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin","volume":"26","author":"Lim S","year":"2024","unstructured":"Lim S, Lee SH, Min KW, et al.. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin. Diabetes Obes Metab. 2024, 26:2188-98. 10.1111\/dom.15526","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15222","article-title":"In praise of pioglitazone: an economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome","volume":"25","author":"Bell DS","year":"2023","unstructured":"Bell DS, Jerkins T. In praise of pioglitazone: an economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. Diabetes Obes Metab. 2023, 25:3093-102. 10.1111\/dom.15222","journal-title":"Diabetes Obes Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi K","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, et al.. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016, 165:305-15. 10.7326\/M15-1774","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy JA","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, et al.. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005, 366:1279-89. 10.1016\/S0140-6736(05)67528-9","journal-title":"Lancet"},{"key":"ref14","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. (2025). Accessed. March 30, 2025: https:\/\/training.cochrane.org\/handbook."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","unstructured":"PROSPERO. international prospective register of systematic reviews. (2025). Accessed: March 06, 2025: https:\/\/www.crd.york.ac.uk\/PROSPERO\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref20","unstructured":"GRADE handbook. (2023). Accessed. October 29, 2023: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html#h.g2dqzi9je57e."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho YK","year":"2024","unstructured":"Cho YK, Kim KS, Lee BW, et al.. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study. Clin Ther. 2024, 46:662-9. 10.1016\/j.clinthera.2024.06.023","journal-title":"Clin Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0314","article-title":"Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial","volume":"48","author":"Heo JH","year":"2024","unstructured":"Heo JH, Han KA, Hong JH, et al.. Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diabetes Metab J. 2024, 48:937-48. 10.4093\/dmj.2023.0314","journal-title":"Diabetes Metab J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12814","article-title":"Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials","volume":"19","author":"Tinahones FJ","year":"2017","unstructured":"Tinahones FJ, Gallwitz B, Nordaby M, G\u00f6tz S, Maldonado-Lutomirsky M, Woerle HJ, Broedl UC. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes Obes Metab. 2017, 19:266-74. 10.1111\/dom.12814","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0779","article-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes","volume":"38","author":"Mathieu C","year":"2015","unstructured":"Mathieu C, Ranetti AE, Li D, et al.. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015, 38:2009-17. 10.2337\/dc15-0779","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01299.x","article-title":"The role of peroxisome proliferator-activated receptor \u03b3 in pancreatic \u03b2 cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus","volume":"12","author":"Gupta D","year":"2010","unstructured":"Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor \u03b3 in pancreatic \u03b2 cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab. 2010, 12:1036-47. 10.1111\/j.1463-1326.2010.01299.x","journal-title":"Diabetes Obes Metab"},{"key":"ref26","article-title":"A study of effects of pioglitazone and rosiglitazone on various parameters in patients of type-2 diabetes mellitus with special reference to lipid profile","volume":"64","author":"Sharma SK","year":"2016","unstructured":"Sharma SK, Verma SH. A study of effects of pioglitazone and rosiglitazone on various parameters in patients of type-2 diabetes mellitus with special reference to lipid profile. J Assoc Physicians India. 2016, 64:24-8.","journal-title":"J Assoc Physicians India"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2460","article-title":"Therapeutic roles of peroxisome proliferator-activated receptor agonists","volume":"54","author":"Staels B","year":"2005","unstructured":"Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005, 54:2460-70. 10.2337\/diabetes.54.8.2460","journal-title":"Diabetes"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13675","article-title":"The effect of thiazolidinediones on body fat redistribution in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Zhang F","year":"2024","unstructured":"Zhang F, Pan X, Zhang X, Tong N. The effect of thiazolidinediones on body fat redistribution in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024, 25:e13675. 10.1111\/obr.13675","journal-title":"Obes Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003","volume":"108","author":"Nesto RW","year":"2003","unstructured":"Nesto RW, Bell D, Bonow RO, et al.. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003, 108:2941-8. 10.1161\/01.CIR.0000103683.99399.7E","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar MJ","year":"2018","unstructured":"van Baar MJ, van Ruiten CC, Muskiet MH, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018, 41:1543-56. 10.2337\/dc18-0588","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis JD","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, et al.. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015, 314:265-77. 10.1001\/jama.2015.7996","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan WN","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, et al.. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016, 374:1321-31. 10.1056\/NEJMoa1506930","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/2042018815574229","article-title":"The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients","volume":"6","author":"Aghamohammadzadeh N","year":"2015","unstructured":"Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, et al.. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015, 6:56-60. 10.1177\/2042018815574229","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0680","article-title":"Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial","volume":"41","author":"Jabbour SA","year":"2018","unstructured":"Jabbour SA, Fr\u00edas JP, Hardy E, Ahmed A, Wang H, \u00d6hman P, Guja C. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018, 41:2136-46. 10.2337\/dc18-0680","journal-title":"Diabetes Care"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve SV","year":"2025","unstructured":"Badve SV, Bilal A, Lee MM, et al.. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025, 13:15-28. 10.1016\/S2213-8587(24)00271-7","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402199-pioglitazone-as-add-on-to-metformin-and-dapagliflozin-yields-significant-enhancements-in-glycemic-control-in-poorly-controlled-type-2-diabetes-a-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T17:09:35Z","timestamp":1758388175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402199-pioglitazone-as-add-on-to-metformin-and-dapagliflozin-yields-significant-enhancements-in-glycemic-control-in-poorly-controlled-type-2-diabetes-a-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.92794","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,20]]}}}